Advaxis Inc

Most Recent

  • uploads///ADXS
    Company & Industry Overviews

    Why Investors Are Excited about Advaxis

    Advaxis (ADXS), in collaboration with Merck (MRK), is conducting a Phase 1 Part 2 trial to evaluate the safety and efficacy of ADXS-PSA.

    By Kenneth Smith
  • uploads///ADXS
    Company & Industry Overviews

    FDA Lifts Hold on Clinical Trial: Major Boost for Advaxis

    In a major development, Advaxis announced on July 13 that the FDA has lifted its hold on the IND (Investigational New Drug) application.

    By Kenneth Smith
  • uploads///blood _
    Company & Industry Overviews

    Why Advaxis Stock Is Soaring Today

    Today, Advaxis (ADXS) is trading at $1.43, which represents a rise of ~16.80% from yesterday’s close of $1.22.

    By Daniel Collins
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    XBI Recovers from Its Slump

    The SPDR S&P Biotech ETF (XBI) and the iShares Nasdaq Biotechnology ETF (IBB) were the top biotechnology ETFs last week, returning 5.3%, and 3.7%.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Advaxis Led the Bottom Ten Biotechnology Stocks by Market Cap

    Advaxis (ADXS), which has a weight of 0.61% in the SPDR S&P Biotechnology (XBI) ETF, rose 24.54% for the week ended September 11, 2015.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.